BioTuesdays: Aethlon readies U.S. study of the Hemopurifier
Aethlon Medical (OTCQB:AEMD), sporting FDA approval of an investigational drug exemption (IDE), plans to begin treating patients infected with hepatitis C virus (HCV) early next year in a feasibility study to demonstrate the safety of its Hemopurifier.
The Hemopurifier is a therapeutic filtration cartridge designed for use on existing dialysis and CRRT machines. The device targets the rapid elimination of circulating infectious disease and cancer targets without removing essential blood components required for health.
“Obtaining FDA permission to initiate human studies has been our most important objective for several years,” chairman and CEO Jim Joyce says in an interview with BioTuesdays.
“Previously, in the treatment of HCV-infected individuals, we have demonstrated that our Hemopurifier could eliminate the presence of HCV in as little a seven days when utilized in combination with interferon-based therapy,” Mr. Joyce says.
....See BioTuesdays for rest of today's feature article on AEMD...